Comparison of the effect on glycemic control between imeglimin and metformin in patients with type 2 diabetes -prospective randomized controlled trial

omoto Hiroshi0 个研究点目标入组 70 人开始时间: 2022年5月11日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Age 20-90 years old
•2) HbA1c 7.0-10.0%
•3) patients who were treated with DPP-4 inhibitors at least for 12 weeks (Sitagliptin, teneligliptin, and anagliptin: from regular dose to maximun dose; vildagliptin, saxagliptin, trelagliptin, linagliptin, alogliptin, and omarigliptin: regular dose)
•4) written informed consent

•1) history of anaphylaxis of imeglimin
•2) inappropriate to increase metformin
•3) unstable retinopathy
•4) severe hepatic dysfunction, renal dysfunction (eGFR<45 mL/min/1.73m2), or heart failure
•5) female patients who are pregnant and/or willing to be pregnant
•6) severe ketosis, diabetic coma
•7) severe infection, surgery, serious trauma
•8) inability to consume an appropriate diet
•9) incompatibility with the trial for other reasons, as determined by a physician

发起方

omoto Hiroshi